OTC •
Healthcare •
Biotechnology •
Quote as of 07/14/2026 14:54
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization0.0512 mln
Float466 mln
Earnings Date08/11/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-13.01
Highly reliable
Relative Strength
50
/ 100
In line with market
Debt / Equity
-0.18
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Regen BioPharma Inc. is a California-based biotechnology company founded in 2012 that works to develop new treatments for cancer and autoimmune diseases by targeting a gene known as NR2F6, which plays a key role in regulating immune cell activity. The company is building a pipeline of therapies that use the body's own immune cells, re-engineered through advanced genetic techniques, to either attack tumors or calm an overactive immune system. Its work spans several treatment approaches, including cell-based therapies, gene-silencing tools, and modified immune cells designed to be more effective and longer-lasting.
